8-K: Vera Therapeutics Announces Positive Progress in IgAN Treatment and Reports Year-End Financials

Vera Therapeutics is on track to announce Phase 3 trial results for its IgAN treatment and plans for FDA submission in 2025, supported by a strengthened balance sheet.

Summary

• Vera Therapeutics reported its fourth quarter and full year 2024 financial results and provided a business update.
• The company is on track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025.
• Vera plans to submit a Biologics License Application (BLA) to the U.S. FDA for accelerated approval in 2H 2025.
• The company is expanding the atacicept clinical development program in multiple autoimmune kidney diseases in 2025.
• Vera completed two equity financings in 2024, raising approximately $593.2 million in net proceeds.
• The company reported a net loss of $152.1 million for the year ended December 31, 2024, compared to a net loss of $96.0 million for the year ended December 31, 2023.
• Vera reported $640.9 million in cash, cash equivalents, and marketable securities as of December 31, 2024, which the company believes is sufficient to fund operations through potential approval and U.S. commercial launch of atacicept.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, FDA designation, and strong cash position. However, the increased net loss and operating expenses temper the overall sentiment.

Positives

• Vera is on track to announce Phase 3 ORIGIN trial results in 2Q 2025.
• The company plans to submit a BLA to the FDA in 2H 2025 for accelerated approval of atacicept in IgAN.
• Vera received FDA Breakthrough Therapy Designation for atacicept in IgAN.
• The company has a strong cash position of $640.9 million as of December 31, 2024, sufficient to fund operations through potential approval and commercial launch.
• Vera is expanding its atacicept development pipeline to include other autoimmune kidney diseases.

Negatives

• Vera reported a net loss of $152.1 million for the year ended December 31, 2024, which is higher than the $96.0 million loss reported for the year ended December 31, 2023.
• Net cash used in operating activities was $134.7 million for the year ended December 31, 2024, compared to $92.2 million for the same period last year.

Risks

• The company's plans to submit a BLA to the FDA and potentially receive approval for atacicept are subject to the regulatory approval process.
• Results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results.
• The company faces risks and uncertainties associated with its business in general, including the impact of macroeconomic and geopolitical events.

Future Outlook

Vera Therapeutics plans to complete enrollment and report primary endpoint results for the Phase 3 ORIGIN trial in 2Q 2025, submit a BLA to the FDA in 2H 2025, and potentially receive FDA approval and launch atacicept commercially in 2026. The company believes its cash position is sufficient to fund operations through potential approval and U.S. commercial launch of atacicept.

Management Comments

• We are on track to announce the primary endpoint result of the ORIGIN Phase 3 study in the second quarter of this year.
• We look forward to submitting a Biologics License Application (BLA) for this potential best-in-class therapy in the second half of this year.
• We are grateful to the study investigators and participants for their ongoing and enthusiastic participation in this program, said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.
• In addition, over the past year we have made progress advancing our broader development pipeline, including additional potential indications for atacicept.

Industry Context

Vera Therapeutics is focused on developing treatments for immunological diseases, specifically IgAN. The company's progress with atacicept and its plans for FDA submission position it to potentially compete with existing and emerging therapies in the autoimmune disease space. The expansion of the atacicept development pipeline to include other autoimmune kidney diseases indicates a broader strategy to address unmet medical needs in this area.

Comparison to Industry Standards

• Atacicept is being positioned as a potential best-in-class therapy targeting B cells to reduce autoantibodies.
• The company highlights that atacicept has been administered to more than 1,500 patients in clinical studies across different indications, suggesting a well-established safety profile.
• The FDA Breakthrough Therapy Designation for atacicept in IgAN indicates that the FDA believes the drug may demonstrate substantial improvement over available therapies.

Management Changes

Stakeholder Impact

• Shareholders: The progress in clinical trials and strong cash position are positive for shareholders.
• Patients: The development of atacicept could provide a new treatment option for patients with IgAN and other autoimmune kidney diseases.
• Employees: The company's growth and development activities could create new job opportunities.

Next Steps

• Complete enrollment in the ongoing pivotal ORIGIN 3 trial in 2Q 2025.
• Announce the primary endpoint result from the ORIGIN 3 trial in 2Q 2025.
• Submit a BLA to the U.S. FDA in 2H 2025 for atacicept in IgAN for accelerated approval.
• Initiate the PIONEER trial in 2025 to evaluate atacicept in expanded IgAN populations and anti-PLA2R positive PMN and anti-nephrin positive FSGS and MCD.
• QM dose finding study initiating in 2025 to evaluate extended dosing.

Key Dates